Replies to post #247701 on Avid Bioservices Inc (CDMO)

[masshysteria]

CP - as long as your girlfriends don't get the short end of the stick (and by that I mean less of your attention), they should consider themselves lucky ;)

Great points and more of a reasoning to tie this company with things much bigger than its share price appears to suggest...

Like you (I think you mentioned this recently, as others have), I think 2016 is a major make or break year (I expect make - by far) and HAS to result in a movement of the share price. It could be down (if things don't work out), which I do not expect, and it could be considerably up due to many outcomes being reached (end of P III trial, more formal messaging from AZN regarding ongoing trials, early Breast readouts, etc.) I'll go as far as saying that if we're anywhere less than $4-$6 by the end of 2016 - Peregrine does not have what it says it has, or someone else built a better mouse trap.

Best and cheers for a great year to come!

MH

Edit: share price target is on the low side of what it should be worth, and does not take deals/buyouts/financial partnerships into accounts. Should those materialize during the year - all bets are off.

[cjgaddy]

CP, most all the other speakers have pictures too, not just Dr. Hutchins!! (I only POSTED Dr. Hutchins' picture!)

See AGENDA:
http://www.immunotherapyforum.com/Content/Agenda/10/

Jan25-27 2016: “Phacilitate's Immunotherapy World Conf.”, WashDC
http://www.immunotherapyforum.com/Content/Conference
---------
Jan25(Day1): Focus Session1, “Cellular Cancer Immunotherapy: Optimizing Combination Therapy Development Strategy”
2:40-2:55pm: Chair's intro, David Lebwohl, NOVARTIS
2:55-3:10pm: Michael Hanna, VACCINOGEN, “The Provocative Issues of Tumor Heterogeneity on Active Specific Immunotherapy...”
3:10-3:25pm: Laura Benjamin, ELI LILLY, “Challenges/Opportunities for Translational Science to Guide Angiogenesis/Combos w/Immunotherapy”
3:25-3:40pm: Taylor Schreiber, HEAT BIOLOGICS, “Dual-Acting Immunotherapy with ComPACT - Vaccination & Co-Stimulation...”
-------
1-25-16 3:40-3:55pm: Jeff T. Hutchins (PEREGRINE'S VP/PreClinRes), “Combination Immunotherapies - Opening the Gate: Increasing Tumor Infiltrating Activated T-cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies”
* Analyzing complimentary mechanisms in therapeutics and building solid partnerships
* Utilizing scientifically-driven data to build a product value story
* Demonstrating how a product fits within a treatment in combination(s) and against competitive therapies
-------
3:55-4:20pm: Robert Preti, PCT(CALADRIUS), “What Does Commercialization Look Like?”